You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rituximab

Showing 1 - 25 of 2,665
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum

Not yet recruiting
  • Neuromyelitis Optica Spectrum Disorders
  • (no location specified)
Sep 29, 2023

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +3 more
  • Clinical Observation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
Feb 2, 2023

Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

Not yet recruiting
  • Splenic Marginal Zone Lymphoma
  • Aarhus, Denmark
  • +4 more
Feb 17, 2023

Nephrotic Syndrome in Children Trial in Chongqing (Rituximab, Mycophenolate Mofetil)

Recruiting
  • Nephrotic Syndrome in Children
  • Rituximab
  • Mycophenolate Mofetil
  • Chongqing, Chongqing, China
    Children's Hospital of Chongqing Medical University
May 3, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)

Not yet recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Polatuzumab vedotin
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 9, 2023

Myasthenia Gravis, Generalized Trial in Roma (Rituximab, Placebo)

Recruiting
  • Myasthenia Gravis, Generalized
  • Rituximab
  • Placebo
  • Roma, Italy
    Policlinico A. Gemelli IRCCS
May 25, 2023

Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)

Completed
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
Jan 30, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

Not yet recruiting
  • CNS Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)

Not yet recruiting
  • Primary Ocular Adnexal MALT Lymphoma
  • Rituximab
  • Involved Site Radiation Therapy
  • (no location specified)
Sep 26, 2023

Nephrotic Syndrome in Children, Rituximab Trial in Hangzhou (Rituximab, Steroid)

Not yet recruiting
  • Nephrotic Syndrome in Children
  • Rituximab
  • Hangzhou, Zhejiang, China
    Children's Hospital, Zhejiang University School of Medicine
Feb 9, 2023

Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • Shanghai, Shanghai, China
    Ruijin Hospital
Nov 14, 2023

Prognostic Model of Rituximab in the Treatment of MN

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • Rituximab
  • (no location specified)
Dec 28, 2022

Selinexor Combined With Lenalidomide and Rituximab in Treatment

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Selinexor combined with lenalidomide and rituximab
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 20, 2023

Renal Transplant Trial in Seoul (Rituximab, intravenous immune globulin)

Completed
  • Renal Transplant
  • Rituximab
  • intravenous immune globulin
  • Seoul, Korea, Republic of
  • +1 more
Oct 25, 2022